Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two senior management appointments at Biogen Idec

This article was originally published in Scrip

Executive Summary

Biogen Idec has named Dr Douglas Williams executive vice-president of R&D and Steven Holtzman executive vice-president of corporate development. Dr Williams will oversee global R&D, including discovery research, development, clinical operations and regulatory affairs, while Mr Holtzman will oversee corporate strategy, business development, portfolio management, programme leadership and the new ventures fund. Dr Williams has more than 20 years' scientific and leadership experience, having most recently served as CEO of ZymoGenetics. Mr Holtzman, who also has more than 20 years' industry experience, was previously founder, chairman and CEO of Infinity Pharmaceuticals. Both will report to Biogen Idec's CEO Dr George Scangos.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts